Adalimumab (D2E7), a fully human anti-TNF-a monoclonal antibody, inhibits the progression of structural joint damage in patients with active RA despite concomitant methotrexate therapy

Category Primary study
JournalArthritis Rheum
Year 2002

This article is included in 1 Systematic review Systematic reviews (1 reference)

This article is part of the following publication threads:
  • ARMADA - DE009 [Anti-TNF Research Study Program of the Monoclonal Antibody Adalimumab [D2E7] in Rheumatoid Arthritis] (5 documents)
This article is part of the following matrixes of evidence:
Loading references information
This article has no abstract
Epistemonikos ID: b30a01a5ee7a1a5a60e47dc5c19273ea2e369a77
First added on: Oct 25, 2017